Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need. The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!